Its label also covers lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease, and slowing kidney decline in those with chronic kidney disease. It is not approved for weight loss; the same drug at higher doses is sold for that as Wegovy.1
What it is
Semaglutide copies a gut hormone called glucagon-like peptide-1 (GLP-1) and acts on the same receptor. The label describes three effects behind its action on blood sugar: it increases insulin release when glucose is high, lowers glucagon secretion, and causes a minor delay in the emptying of the stomach after a meal.1 It belongs to the class called GLP-1 receptor agonists.
Ozempic comes as a pen that holds several weekly doses, and as single-dose prefilled syringes. It is injected under the skin of the abdomen, thigh or upper arm, once a week, at any time of day, with or without meals.1
Ozempic tablets are a separate product with their own label, shared with Rybelsus, the older semaglutide tablet. They come in 1.5, 4 and 9 mg and are taken once a day in the morning on an empty stomach with up to 4 ounces of water. Food, drinks and other pills wait at least 30 minutes. They are approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of them. The label warns that Rybelsus and Ozempic tablets are not substitutable milligram for milligram, so a switch between them, or from the injection, follows the prescriber's instructions.2 The rest of this page is about the injection.
What the label approves it for
The label lists three uses, all in adults with type 2 diabetes.1
- As an addition to diet and exercise, to improve blood sugar control.
- To reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease.
- To reduce the risk of sustained decline in kidney function, end-stage kidney disease and cardiovascular death in those with chronic kidney disease.
Weight loss is not on the list. Prescribing Ozempic to someone without type 2 diabetes for weight loss is off-label use. Wegovy, the semaglutide brand approved for weight management, goes up to a weekly 2.4 mg or 7.2 mg; Ozempic stops at 2 mg.1,3
Doses
Treatment starts at 0.25 mg once a week for 4 weeks. The label sets this low start, and the slow climb after it, to reduce the risk of stomach and gut side effects. After that the dose goes to 0.5 mg, and if more control is needed, to 1 mg and then 2 mg, each after at least 4 weeks on the previous dose.1 At the fastest pace the label allows, the first 2 mg dose comes in week 13. Our page on the Ozempic dosing schedule puts the steps on a calendar.
What it did in trials
In the label's 30-week trial of Ozempic on its own, in adults whose diabetes was not controlled by diet and exercise, HbA1c started at about 8%. It fell by 1.4 percentage points on 0.5 mg and 1.6 on 1 mg, against 0.1 on placebo. An HbA1c under 7% was reached by 73% on 0.5 mg and 70% on 1 mg, against 28% on placebo.1
Side effects and warnings
The most common side effects are in the stomach and gut: nausea, vomiting, diarrhea, abdominal pain and constipation. In the label's placebo-controlled trials, nausea was reported by 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo.1
The label carries a boxed warning about thyroid C-cell tumors, which semaglutide caused in rodents; it is not known whether it does so in people. Ozempic must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. Other warnings cover pancreatitis, diabetic eye complications, low blood sugar with insulin or a sulfonylurea, kidney injury from fluid loss, gallbladder disease and aspiration during anesthesia.1 Our page on Ozempic side effects gives the rates.
Ozempic in eight lines
| Fact | Ozempic |
|---|---|
| Active ingredient | Semaglutide |
| Maker | Novo Nordisk |
| First U.S. approval | 2017 |
| How often | Injection weekly; tablets daily |
| Injection doses | 0.25 mg to start, then 0.5, 1 and 2 mg |
| Half-life | About 1 week |
| In the body after the last dose | About 5 weeks |
| Approved for weight loss | No |
OZEMPIC injection prescribing information, revised May 2026; RYBELSUS and OZEMPIC tablets label, revised January 2026.1,2
Related terms
Ozempic, Wegovy and Rybelsus all contain semaglutide; Rybelsus is the daily tablet for type 2 diabetes that shares its label with Ozempic tablets. Mounjaro and Zepbound contain tirzepatide, which acts on the GLP-1 receptor and a second one, the GIP receptor. Our comparisons of Ozempic and Wegovy and of Ozempic and Mounjaro set the labels side by side.
Sources
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 2, 4, 5, 6.1, 12 and 14. accessdata.fda.gov
- RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published August 19, 2026; sections 1, 2 and 3. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 2. accessdata.fda.gov
Related analyses
Ozempic dosing schedule: 0.25 mg to 2 mg, week by week, with your own dates
Ozempic side effects: how common each one is by dose, and when they ease
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
Log each Ozempic dose and see your own week on one screen.
Open Dose Insider